News | July 31, 2024
Granules India posts Q1 FY25 consolidated PAT higher at Rs. 134.64 Cr
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
Subscribe To Our Newsletter & Stay Updated
